Innovodigm, a Kolkata-based medtech innovator, has raised ₹5.5 crore in a seed funding round led by IAN Group, with ₹4.5 crore contributed by the angel network, and the remainder from PadUp Ventures.
The fresh funds raised will be used to optimize its manufacturing processes, expand infrastructure and scale its team as the startup prepares for third-party preclinical validation and clinical trials.
Founded in 2020 by Jhimli Manna and Ayan Chatterjee, Innovodigm is developing a proprietary Microneedle Array Patch (MAP) platform—a needle-free, thermostable method of vaccine delivery aimed at addressing limitations in traditional injectable immunization. Innovodigm’s micro-array patches contain thermostabilized vaccines that remain viable for up to 120 days at 40°C.
The technology is patent-protected, needle-free, waste-reducing, and easy to administer, requiring minimal training and enabling safer immunization campaigns.
The startup plans to expand across India and other low-and middle-income countries, adapting its patch for vaccines like measles, hepatitis, influenza, and others. It’s also working to build local manufacturing hubs to produce patches closer to where they’re needed most.
The company has already signed a Material Transfer Agreement (MTA) with a leading Indian vaccine manufacturer.
Dr Jhimli Manna, CEO of Innovodigm said, “Spinning out from IIT Kharagpur’s Microelectronics and MEMS Lab has been instrumental in building our innovation on deep scientific roots. This seed funding enables us to take our MAP platform from lab to field and make a global impact by transforming vaccine delivery and accessibility.”
IAN Group’s Padmaja Ruparel said, “Innovodigm’s platform has the potential to revolutionize global vaccine distribution, particularly in geographies where cold-chain and needle-based immunization are limiting factors. Their deep-tech foundation and strong regulatory roadmap make this a standout health-tech opportunity.”
